How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers

To evaluate China's current rifampin-resistant tuberculosis (RR-TB) screening strategy from stakeholders' perspectives, the perceptions, attitudes, and interests of 245 stakeholders from three eastern, central, and western China provinces on RR-TB screening strategies, were investigated th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Qianhui Hua, Hong Xu, Xinyi Chen, Junhang Pan, Ying Peng, Wei Wang, Bin Chen, Jianmin Jiang
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	rifampin-resistant tuberculosis screening policy stakeholders attitudes Public aspects of medicine RA1-1270
Acceso en línea:	https://doaj.org/article/2c9138ae51ab42d4bc35f65e327774e9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2c9138ae51ab42d4bc35f65e327774e9
record_format	dspace
spelling	oai:doaj.org-article:2c9138ae51ab42d4bc35f65e327774e92021-11-30T17:52:14ZHow to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers2296-256510.3389/fpubh.2021.736632https://doaj.org/article/2c9138ae51ab42d4bc35f65e327774e92021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fpubh.2021.736632/fullhttps://doaj.org/toc/2296-2565To evaluate China's current rifampin-resistant tuberculosis (RR-TB) screening strategy from stakeholders' perspectives, the perceptions, attitudes, and interests of 245 stakeholders from three eastern, central, and western China provinces on RR-TB screening strategies, were investigated through stakeholder survey and interview. The attitudes toward three RR-TB screening strategies were statistically different: inclination to choose who to screen (Z = 98.477; P < 0.001), funding for rapid diagnostic technology screening either by reimbursed health insurance or directly subsidized financial assistance (Z = 4.142, P < 0.001), and respondents' attitude during RR-TB screening implementation levels (Z = 2.380, P = 0.017). In conclusion, RR-TB screening scope could be expanded by applying rapid diagnostic technologies. Provinces with different economic status could adjust their screening policies accordingly.Qianhui HuaHong XuXinyi ChenJunhang PanYing PengWei WangBin ChenJianmin JiangJianmin JiangFrontiers Media S.A.articlerifampin-resistant tuberculosisscreeningpolicystakeholdersattitudesPublic aspects of medicineRA1-1270ENFrontiers in Public Health, Vol 9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	rifampin-resistant tuberculosis screening policy stakeholders attitudes Public aspects of medicine RA1-1270
spellingShingle	rifampin-resistant tuberculosis screening policy stakeholders attitudes Public aspects of medicine RA1-1270 Qianhui Hua Hong Xu Xinyi Chen Junhang Pan Ying Peng Wei Wang Bin Chen Jianmin Jiang Jianmin Jiang How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers
description	To evaluate China's current rifampin-resistant tuberculosis (RR-TB) screening strategy from stakeholders' perspectives, the perceptions, attitudes, and interests of 245 stakeholders from three eastern, central, and western China provinces on RR-TB screening strategies, were investigated through stakeholder survey and interview. The attitudes toward three RR-TB screening strategies were statistically different: inclination to choose who to screen (Z = 98.477; P < 0.001), funding for rapid diagnostic technology screening either by reimbursed health insurance or directly subsidized financial assistance (Z = 4.142, P < 0.001), and respondents' attitude during RR-TB screening implementation levels (Z = 2.380, P = 0.017). In conclusion, RR-TB screening scope could be expanded by applying rapid diagnostic technologies. Provinces with different economic status could adjust their screening policies accordingly.
format	article
author	Qianhui Hua Hong Xu Xinyi Chen Junhang Pan Ying Peng Wei Wang Bin Chen Jianmin Jiang Jianmin Jiang
author_facet	Qianhui Hua Hong Xu Xinyi Chen Junhang Pan Ying Peng Wei Wang Bin Chen Jianmin Jiang Jianmin Jiang
author_sort	Qianhui Hua
title	How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers
title_short	How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers
title_full	How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers
title_fullStr	How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers
title_full_unstemmed	How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers
title_sort	how to effectively identify patients with rifampin-resistant tuberculosis in china: perspectives of stakeholders among service providers
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/2c9138ae51ab42d4bc35f65e327774e9
work_keys_str_mv	AT qianhuihua howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders AT hongxu howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders AT xinyichen howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders AT junhangpan howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders AT yingpeng howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders AT weiwang howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders AT binchen howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders AT jianminjiang howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders AT jianminjiang howtoeffectivelyidentifypatientswithrifampinresistanttuberculosisinchinaperspectivesofstakeholdersamongserviceproviders
_version_	1718406369602699264

How to Effectively Identify Patients With Rifampin-Resistant Tuberculosis in China: Perspectives of Stakeholders Among Service Providers

Ejemplares similares